×
Wednesday, December 8, 2021

Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer | Antibodies | News Channels - PipelineReview.com

Last updated Friday, October 15, 2021 03:45 ET , Source: NewsService